Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Solid Biosciences (SLDB), a precision genetic medicines developer focusing on neuromuscular and cardiac diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Bo Cumbo, President and CEO, will deliver a presentation on Wednesday, January 15, 2025, at 3:45 p.m. PT (6:45 p.m. ET).
The presentation will be accessible through a live webcast on the Company's website's Investors section under the Events page. A replay of the webcast will remain available for 30 days following the event. Institutional investors seeking meetings with management during the conference are advised to contact their J.P. Morgan representatives.
Solid Biosciences (SLDB), sviluppatore di medicinali genetici di precisione focalizzato sulle malattie neuromuscolari e cardiache, ha annunciato la sua partecipazione al 43° Meeting Annuale della Sanità J.P. Morgan. Bo Cumbo, Presidente e CEO, presenterà mercoledì 15 gennaio 2025, alle 15:45 PT (18:45 ET).
La presentazione sarà accessibile tramite una trasmissione in diretta sul sito web della Società nella sezione Investitori, sotto la pagina Eventi. Una registrazione della trasmissione rimarrà disponibile per 30 giorni dopo l'evento. Gli investitori istituzionali che desiderano incontrare la direzione durante la conferenza sono invitati a contattare i loro rappresentanti J.P. Morgan.
Solid Biosciences (SLDB), un desarrollador de medicamentos genéticos de precisión enfocado en enfermedades neuromusculares y cardíacas, ha anunciado su participación en la 43ª Conferencia Anual de Atención Médica J.P. Morgan. Bo Cumbo, Presidente y CEO, hará una presentación el miércoles 15 de enero de 2025, a las 3:45 p.m. PT (6:45 p.m. ET).
La presentación será accesible a través de una transmisión en vivo en la sección de Inversores del sitio web de la compañía en la página de Eventos. Se mantendrá una repetición de la transmisión durante 30 días después del evento. Se aconseja a los inversores institucionales que deseen reuniones con la dirección durante la conferencia que se comuniquen con sus representantes de J.P. Morgan.
솔리드 바이오사이언스(SLDB), 신경근육 및 심장 질환에 초점을 맞춘 정밀 유전자 의약품 개발업체가 제43회 JP모건 헬스케어 컨퍼런스 참여를 발표했습니다. 보 컴보 CEO는 2025년 1월 15일 수요일 오후 3시 45분 PT (오후 6시 45분 ET)에 발표를 진행할 예정입니다.
발표는 회사 웹사이트의 투자자 섹션 이벤트 페이지를 통해 라이브 웹캐스트로 시청할 수 있습니다. 행사가 끝난 후 30일 동안 다시보기 서비스를 제공할 예정입니다. 컨퍼런스 기간 동안 경영진과의 미팅을 원하는 기관 투자자들은 JP모건 대표에게 문의하시기 바랍니다.
Solid Biosciences (SLDB), un développeur de médicaments génétiques de précision axé sur les maladies neuromusculaires et cardiaques, a annoncé sa participation à la 43e Conférence Annuelle de la Santé J.P. Morgan. Bo Cumbo, président et PDG, fera une présentation le mercredi 15 janvier 2025, à 15h45 PT (18h45 ET).
La présentation sera accessible via un webinaire en direct dans la section Investisseurs du site web de l'entreprise, sous la page Événements. Une répétition du webinaire sera disponible pendant 30 jours après l'événement. Les investisseurs institutionnels souhaitant des réunions avec la direction pendant la conférence sont invités à contacter leurs représentants J.P. Morgan.
Solid Biosciences (SLDB), ein Entwickler präziser gentherapeutischer Mittel mit Schwerpunkt auf neuromuskulären und Herzerkrankungen, hat seine Teilnahme an der 43. Jahrestagung der J.P. Morgan Healthcare Conference bekanntgegeben. Bo Cumbo, Präsident und CEO, wird am Mittwoch, den 15. Januar 2025, um 15:45 Uhr PT (18:45 Uhr ET) eine Präsentation halten.
Die Präsentation wird über einen Live-Stream im Investorenbereich der Unternehmenswebsite unter der Veranstaltungsseite zugänglich sein. Eine Aufzeichnung des Webcasts wird 30 Tage nach der Veranstaltung verfügbar bleiben. Institutionelle Investoren, die während der Konferenz Meetings mit dem Management suchen, werden gebeten, ihre J.P. Morgan Ansprechpartner zu kontaktieren.
- None.
- None.
CHARLESTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 3:45 p.m. PT (6:45 p.m. ET).
A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for 30 days on the Events page.
Institutional investors interested in meeting with management during the conference may reach out to their J.P. Morgan representatives.
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-212 for the treatment of Friedreich’s ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
FAQ
When is Solid Biosciences (SLDB) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch Solid Biosciences' (SLDB) J.P. Morgan Healthcare Conference presentation?
How long will the replay of SLDB's J.P. Morgan Healthcare Conference presentation be available?
What therapeutic areas does Solid Biosciences (SLDB) focus on?
How can institutional investors arrange meetings with SLDB management during the conference?
